Alan K. Burnett

36.1k total citations · 12 hit papers
353 papers, 23.6k citations indexed

About

Alan K. Burnett is a scholar working on Hematology, Molecular Biology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Alan K. Burnett has authored 353 papers receiving a total of 23.6k indexed citations (citations by other indexed papers that have themselves been cited), including 275 papers in Hematology, 135 papers in Molecular Biology and 93 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Alan K. Burnett's work include Acute Myeloid Leukemia Research (231 papers), Acute Lymphoblastic Leukemia research (92 papers) and Retinoids in leukemia and cellular processes (61 papers). Alan K. Burnett is often cited by papers focused on Acute Myeloid Leukemia Research (231 papers), Acute Lymphoblastic Leukemia research (92 papers) and Retinoids in leukemia and cellular processes (61 papers). Alan K. Burnett collaborates with scholars based in United Kingdom, United States and Denmark. Alan K. Burnett's co-authors include Keith Wheatley, Robert K. Hills, David Grimwade, Anthony H. Goldstone, Bob Löwenberg, Helen M. Walker, Christine J. Harrison, G Harrison, Ian Hann and James R. Downing and has published in prestigious journals such as New England Journal of Medicine, The Lancet and The Journal of Experimental Medicine.

In The Last Decade

Alan K. Burnett

346 papers receiving 23.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

2009 2.4k citations Hartmut Döhner, Elihu H. Estey et al. Blood profile →
The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial

1998 2.1k citations David Grimwade, Helen M. Walker et al. Blood profile →
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

2010 1.3k citations David Grimwade, Robert K. Hills et al. Blood profile →
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials

2001 1.2k citations Panagiotis Kottaridis, Rosemary E. Gale et al. Blood profile →
Acute Myeloid Leukemia

1999 1.0k citations Bob Löwenberg, Alan K. Burnett et al. profile →
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

2008 605 citations Miguel Á. Sanz, David Grimwade et al. Blood profile →
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

2007 537 citations Anthony H. Goldstone, Susan Richards et al. Blood profile →
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia

2007 522 citations Rosemary E. Gale, Alan K. Burnett et al. Blood profile →
Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

2010 490 citations Alan K. Burnett, Robert K. Hills et al. Journal of Clinical Oncology profile →
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

2014 479 citations Robert K. Hills, Frederick R. Appelbaum et al. profile →
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial

2015 346 citations Alan K. Burnett, Nigel H. Russell et al. profile →
Acute myeloid leukaemia

2016 289 citations Rosemary E. Gale, Clara D. Bloomfield et al. profile →

Peers

Countries citing papers authored by Alan K. Burnett

Since Specialization

Citations

This map shows the geographic impact of Alan K. Burnett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan K. Burnett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan K. Burnett more than expected).

Fields of papers citing papers by Alan K. Burnett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan K. Burnett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan K. Burnett. The network helps show where Alan K. Burnett may publish in the future.

Co-authorship network of co-authors of Alan K. Burnett

This figure shows the co-authorship network connecting the top 25 collaborators of Alan K. Burnett. A scholar is included among the top collaborators of Alan K. Burnett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan K. Burnett. Alan K. Burnett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A randomised evaluation of low‐dose Ara‐C plus pegylated recombinant arginase BCT‐100 versus low dose Ara‐C in older unfit patients with acute myeloid leukaemia: Results from the LI‐1 trial 2022 ·British Journal of Haematology ·Francis Mussai, Carmela De Santo, Paul Cheng, Ian F. Thomas, Cono Ariti, (unknown), (unknown), (unknown), (unknown), Alan K. Burnett, Steven Knapper, Priyanka Mehta, Mary Frances McMullin, Mhairi Copland, Nigel H. Russell, Mike Dennis	7
2	Therapy for isocitrate dehydrogenase 2 (IDH2)^R172‐mutant acute myeloid leukaemia 2021 ·British Journal of Haematology ·David C. Linch, Robert K. Hills, Alan K. Burnett, Nigel H. Russell, Rosemary E. Gale	2
3	Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses 2020 ·Journal of Clinical Oncology ·Alan K. Burnett, Nigel H. Russell, Robert K. Hills, Steven Knapper, Sylvie Freeman, Brian J.P. Huntly, Richard E. Clark, Ian F. Thomas, Lars Kjeldsen, Mary Frances McMullin, Mark W. Drummond, Jonathan Kell, Ruth Spearing	19
4	Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia 2019 ·Blood Advances ·Paul Milne, Charlotte S. Wilhelm-Benartzi, Michael R. Grunwald, Venetia Bigley, Richard Dillon, Sylvie Freeman, Kathleen Gallagher, (unknown), Sarah Pagan, Helen Marr, Gail Jones, Anne M. Dickinson, Angela Grech, Alan K. Burnett, Nigel H. Russell, Mark J. Levis, Steven Knapper, Matthew Collin	17
5	Prognostic Significance of NPM1 Mutations in the Absence of FLT3 –Internal Tandem Duplication in Older Patients With Acute Myeloid Leukemia: A SWOG and UK National Cancer Research Institute/Medical Research Council Report 2015 ·Journal of Clinical Oncology ·Fabiana Ostronoff, Megan Othus, (unknown), Elihu H. Estey, Frederick R. Appelbaum, Anna Evans, John E. Godwin, Amanda Gilkes, Kenneth J. Kopecky, Alan K. Burnett, Alan F. List, Min Fang, Vivian G. Oehler, Stephen H. Petersdorf, Era L. Pogosova‐Agadjanyan, Jerald P. Radich, Cheryl L. Willman, Soheil Meshinchi, Derek L. Stirewalt	96
6	Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial 2013 ·Journal of Clinical Oncology ·Alan K. Burnett, Nigel H. Russell, Robert K. Hills, Ann E. Hunter, Lars Kjeldsen, John Liu Yin, Brenda Gibson, Keith Wheatley, Donald Milligan	289
7	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet breakdown → 2009 ·Blood ·Hartmut Döhner, Elihu H. Estey, Sergio Amadori, Frederick R. Appelbaum, Thomas Büchner, Alan K. Burnett, Hervé Dombret, Pierre Fenaux, David Grimwade, Richard A. Larson, Francesco Lo‐Coco, Tomoki Naoe, Dietger Niederwieser, Gert J. Ossenkoppele, Miguel Á. Sanz, Jorge Sierra, Martin S. Tallman, Bob Löwenberg, Clara D. Bloomfield	2350
8	THE PROGNOSTIC ROLE OF C-FLIP IN AML 2009 ·(unknown), M. F. McMullin, Ken Mills, Robert K. Hills, Amanda Gilkes, Alan K. Burnett, Patrick Johnston, Daniel B. Longley	1
9	In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993) breakdown → 2007 ·Blood ·Anthony H. Goldstone, Susan Richards, Hillard M. Lazarus, Martin S. Tallman, Georgina Buck, Adele K. Fielding, Alan K. Burnett, Raj Chopra, Peter H. Wiernik, Letizia Foroni, Elisabeth Paietta, Mark R. Litzow, David I. Marks, Jill Durrant, Andrew McMillan, Ian M. Franklin, Selina M. Luger, Niculae Ciobanu, Jacob M. Rowe	537
10	Sequential Influences of Leukemia-Specific and Genetic Factors on P-Glycoprotein Expression in Blasts from 817 Patients Entered into the National Cancer Research Network Acute Myeloid Leukemia 14 and 15 Trials 2007 ·Clinical Cancer Research ·Claire Seedhouse, Martin Grundy, P. Bruce White, Yun Li, Janet Fisher, (unknown), Anthony V. Moorman, T. G. Hoy, Nigel H. Russell, Alan K. Burnett, Monica Pallis	34
11	The presence of a FLT3 mutation in AML adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the MRC AML 10 and 12 trials. 2000 ·Blood ·Panagiotis Kottaridis, (unknown), Marion E. Frew, G Harrison, Stephen E. Langabeer, (unknown), Hamish Walker, Keith Wheatley, David Bowen, Alan K. Burnett, A H Goldstone, D C Linch	7
12	Detection of minimal residual disease (MRD) in APL by "real-time" RT-PCR: Analysis of cases entered into the UK MRC ATRA trial. 1999 ·Blood ·David Grimwade, Daniela Diverio, G Harrison, (unknown), Joseph P. Rodgers, (unknown), A H Goldstone, Ellen Solomon, Alan K. Burnett	8
13	Mutant N-RAS blocks granulocytic differentiation of human cd34+ cells 1998 ·ORCA Online Research @Cardiff (Cardiff University) ·Richard L. Darley, T. G. Hoy, Linda C. Robinson, Alan K. Burnett	1
14	Outcome of acute myeloid leukaemias affecting core binding factor subunits: the UK MRC experience 1997 ·ORCA Online Research @Cardiff (Cardiff University) ·Alan K. Burnett, Keith Wheatley, Stephen E. Langabeer, Helen M. Walker, (unknown), Anthony P. Goldstone, (unknown), (unknown)	1
15	Reduced growth of normal myeloid progenitors on MDS stroma is unrelated to confluence 1996 ·PubMed Central ·G. B. Tennant, (unknown), Alan K. Burnett	3
16	Mutant N-RAS induces erythroid lineage dysplasia in human CD34(+) progenitor cells 1995 ·ORCA Online Research @Cardiff (Cardiff University) ·Richard L. Darley, Paul Baines, (unknown), Alan K. Burnett	1
17	A simple, robust and highly predictive prognostic index for the determination of risk directed therapy in acute myeloid leukaemia (AML) derived from the United Kingdom medical research council (MRC) AML10 trial. 1995 ·Blood ·Keith Wheatley, Alan K. Burnett, A H Goldstone, I M Hann, (unknown), J. K. H. Rees, Richard Gray	13
18	Homozygous MHC Genotypes and Longevity 1994 ·Human Heredity ·(unknown), Ken Mills, Dairena Gaffney, (unknown), I. Galbraith, Nancy Henderson, Alan K. Burnett	15
19	Consensus Conference on Intensive Chemotherapy Plus Hematopoietic Stem-Cell Transplantation in Malignancies: Lyon, France, June 4-6, 1993. 1994 ·Journal of Clinical Oncology ·Bertrand Coiffier, Thierry Philip, Alan K. Burnett, Michel Symann	30
20	Distribution of leukemia, lymphoma, and allied disease in parts of Great Britain: analysis by administrative districts and simulations of adjacencies. Leukaemia Research Fund 1984 Data Collection Group. 1987 ·PubMed ·Nicholas A. Barnes, (unknown), C C Bird, J W Bradfield, I L Brown, Alan K. Burnett, Reed A. Cartwright, (unknown), Margaret Edwards, (unknown)	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact